November 6, 2017
TRANS GENIC INC.
(Code No.2342 TSE Mothers)

# TRANS GENIC to Enter into Exclusive Licensing Agreement on Mouse model of Nonalcoholic Steatohepatitis

TRANS GENIC INC. (CEO: Kenji Fukunaga, Fukuoka-city, Fukuoka, Japan) hereby announces that, it has entered into exclusive licensing agreement with Professor Toru Miyazaki (Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo) on AIM (Apoptosis inhibitor of macrophage)-deficient mice for the use as mouse model of nonalcoholic steatohepatitis (NASH).

Under this licensing agreement, TRANS GENIC will exclusively produce and distribute the mouse model of NASH. Also, New Drug Research Center Inc., a subsidiary of TRANS GENIC, will launch non-clinical test service using this mouse model.

Mouse model of NASH is induced to develop fatty liver, hepatic fibrosis, hepatic cirrhosis, and even hepatocellular carcinoma more dominantly than wild-type mice by loading high-fat diet. Since this mouse model effectively mimics the clinical condition of NASH in each stage, it is expected to contribute to therapeutic drug development for NASH, which is increasing with the growing number of obese people.

TRANS GENIC aims to augment revenue by the development of high-margin mouse models and the creation of synergistic effect between each business, which is stated in the publicly announced new basic strategy of mid-term business planning "Vision2020". TRANS Genic will promote the growth strategy by conducting non-clinical test service using this mouse model.

The effects of this licensing agreement on the financial performance for the fiscal term 2017 are not yet determined. TRANS GENIC will enhance the business performance aggressively by providing highly specific products and services.

◆ Related products/service of TRANS GENIC: Mouse models
http://www.transgenic.co.jp/en/products/mice-product/model.php

◆ Reference

・Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation
Natsumi Maehara, Satoko Ara, Mayumi Mori, Yoshihiro Iwamura, Jun Kurokawa, Toshihiro Kai, Shunsuke Kusunoki, Kaori Taniguchi, Kazutaka Ikeda, Osamu Ohara, Ken-ichi Yamamura, Toru Miyazaki. Cell Rep. 1, 61-74 (2014).

◆ Glossary: Nonalcoholic steatohepatitis (NASH)

Nonalcoholic steatohepatitis (NASH) is a type of hepatitis caused by a buildup of fat in the liver. Many affected patients have overeating habit, lack of exercise, obesity (particularly:

visceral obesity), diabetes, and hyperlipidemia. The clinical condition of NASH includes fat accumulation in liver cells as well as hepatic inflammation and fibrosis, which may progress to cirrhosis and liver cancer. The number of NASH patients is estimated to over 3 million in Japan, and 30 million in USA (reference: Nikkei Bio Almanac 2017), but countermeasures for NASH is not yet sufficient. The number of liver cancer patients progressed from NASH has continued to rise in recent years.

Contact for inquiries and additional information：
TRANS GENIC INC.
Yutaka Funabashi, Director
Telephone +81-(0)3-6551-2601